News

Palatin and King are jointly developing the drug for the treatment of both male and female sexual dysfunction. The primary objective of these two dose-ranging clinical trials is

This is only the second biosimilar product to receive EU marketing authorization from the European Commission. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for

The standard chemotherapy for the condition is bacillus calmette-guerin (BCG), a live, attenuated strain of mycobacterium bovis, a therapy that is often associated with treatment-limiting side effects. In

In the study the 24-hour blood pressure profile of HCT 3012 and naproxen, a commonly used anti-inflammatory drug, will be compared. The anti-inflammatory agents currently used in the

The phase I trial is a placebo controlled, randomized, dose escalating study, which will evaluate the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125.

The collaboration aims to advance the performance of cell-based ion channel assays in screening applications. “We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for

The research appears in the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal. Any new drugs that could be developed to block this

The special protocol assessment (SPA) enables DeCode to proceed with the recruitment of participants for the phase III trial. The SPA is an agreement between the FDA and

The investigators concluded that OGX-011 in combination with the chemotherapeutic agents was well tolerated at the doses studied and most toxicities were typical for gemcitabine/cisplatin. The one-year survival